Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697486 | 1.00 | HTR2C (0.46) | HTR2CHTR1FSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1697782 | 1.00 | HTR2C (0.46) | HTR2CHTR1FSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13713476 | 0.82 | HTR6 (0.41) | HTR1FSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL71056 | 0.82 | HTR6 (0.41) | HTR1FSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL6612954 | 0.81 | HTR6 (0.40) | HTR1FSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL3123499 | 0.81 | HTR6 (0.40) | HTR1FSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL27565324 | 0.80 | HTR2C (0.51) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL19139827 | 0.77 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL4676075 | 0.76 | HTR2C (0.57) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL9966799 | 0.74 | ACACB (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588451-B1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| EP-2588451-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| CN-103080087-A | Piperidine derivatives and their use for the treatment of metabolic disorders | BOEHRINGER INGELHEIM INT | 2013-05-01 | — | — | CN | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | HTR2C 691/4885HTR1F 1005/4885SLC6A2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.